Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

The immune checkpoint inhibitor nivolumab inhibits the programmed death 1 receptor and suppresses the immune resistance of cancer cells. This is a long‐term follow up of a single‐arm, open‐label, multicenter, phase II study of nivolumab in untreated Japanese patients with stage III/IV or recurrent m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Naoya, Kiyohara, Yoshio, Uhara, Hisashi, Uehara, Jiro, Fujisawa, Yasuhiro, Takenouchi, Tatsuya, Otsuka, Masaki, Uchi, Hiroshi, Ihn, Hironobu, Hatsumichi, Masahiro, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549931/
https://www.ncbi.nlm.nih.gov/pubmed/30959557
http://dx.doi.org/10.1111/cas.14015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549931/
https://www.ncbi.nlm.nih.gov/pubmed/30959557
http://dx.doi.org/10.1111/cas.14015

Ejemplares similares